Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
The aim of this study was to identify potential microRNAs and genes associated with drug resistance in ovarian cancer through web-available microarrays. The drug resistant-related microRNA microarray dataset GS54665 and mRNA dataset GSE33482, GSE28646, and GSE15372 were downloaded from the Gene Expression Omnibus database. Dysregulated microRNAs/genes were screened with GEO2R and were further identified in SKOV3 (SKOV3/DDP) and A2780 (A2780/DDP) cells by real-time quantitative PCR (qRT-PCR), and then their associations with drug resistance was analyzed by comprehensive bioinformatic analyses. Nine microRNAs (microRNA-199a-5p, microRNA-199a-3p, microRNA-199b-3p, microRNA-215, microRNA-335, microRNA-18b, microRNA-363, microRNA-645 and microRNA-141) and 38 genes were identified to be differentially expressed in drug-resistant ovarian cancer cells, with seven genes (NHSL1, EPHA3, USP51, ZSCAN4, EPHA7, SNCA and PI15) exhibited exactly the same expression trends in all three microarrays. Biological process annotation and pathway enrichment analysis of the 9 microRNAs and 38 genes identified several drug resistant-related signaling pathways, and the microRNA-mRNA interaction revealed the existence of a targeted regulatory relationship between the 9 microRNAs and most of the 38 genes. The expression of 9 microRNAs and the 7 genes by qRT-PCR in SKOV3/DDP and A2780/DDP cells indicating a consistent expression profile with the microarrays. Among those, the expression of EPHA7 and PI15 were negatively correlated with that of microRNA-141, and they were also identified as potential targets of this microRNA via microRNA-mRNA interaction. We thus concluded that microRNA-141, EPHA7, and PI15 might jointly participate in the regulation of drug resistance in ovarian cancer and serve as potential targets in targeted therapies.
Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021, Guangxi, P.R. China.
Jing
J
Zou
Medical Scientific Research Centre, Guangxi Medical University Nanning 530021, Guangxi, P.R. China.
Fuqiang
F
Yin
Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021, Guangxi, P.R. China.
Qi
Q
Wang
Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021, Guangxi, P.R. China.
Wei
W
Zhang
Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021, Guangxi, P.R. China.
Li
L
Li
D014408:Biomarkers, Tumor / Q000235:genetics*; D045744:Cell Line, Tumor; D019295:Computational Biology; D030541:Databases, Genetic; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods*; D015972:Gene Expression Regulation, Neoplastic; D053263:Gene Regulatory Networks; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D053491:Proteinase Inhibitory Proteins, Secretory / Q000235:genetics / Q000378:metabolism; D036141:Receptor, EphA7 / Q000235:genetics / Q000378:metabolism
D014408:Biomarkers, Tumor; D035683:MicroRNAs; D053491:Proteinase Inhibitory Proteins, Secretory; D036141:Receptor, EphA7
Ovarian cancer; bioinformatics; drug resistance; expression profiling microarray; gene; microRNA